Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Interestingly, celebrities like Elon Musk, Oprah Winfrey and Amy Schumer, among others, have also endorsed drugs like Ozempic ...

But at this point, Eli Lilly is stacking wins, and Novo is running out of room to surprise. Investors will be watching the next data drop closelybecause in the high-stakes obesity drug market ...

Eli Lilly and Company (NYSE:LLY), a pharmaceutical giant with a market capitalization of $672 billion, has been making waves with its innovative treatments for diabetes and obesity. According to ...

This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously ...